CareDx To Present at the H.C. Wainwright 25th Annual Global Investment Conference
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicallydifferentiated, high-value healthcare solutions for transplant patients and caregivers ? today announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference.
CareDx's management is scheduled to present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 12:30 PM PT / 3:30 PM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx's investor relations website at: investors.caredxinc.com.
About CareDx ? The Transplant Companytm
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Fun88, a leading company in sports and entertainment, proudly announces its official title sponsorship with the Vizag Warriors for the Andhra Premier League (APL)....
KLab Inc., a leader in online mobile games, announced that its hit 3D action game Bleach: Brave Souls will be holding a Bleach: Brave Souls 9th Anniversary Bankai Live! on Sunday, July 14, 2024 from 18:30 (JST/UTC+9). See the original press release...
Azentio Software ("Azentio") - a leading end-to-end software company specializing in the BFSI sector, today announced the appointment of Aarthi Ramesh as Chief Customer Officer and Emma Foley as Chief Marketing Officer....
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Bel Group, today announced their long-term partnership to accelerate the food industry's transformation toward a more sustainable model. The companies will play a pivotal role in shaping...
